Stem Cell Treatment
 
most experienced in the industry...
                                                    Read More
Affordable Plastic Surgery

Savings of 70-80% on Plastic Surgery Procedures...

                                                              Read More

The Eastern Hepatobiliary Surgery Hospital


The Eastern Hepatobiliary Surgery Hospital (EHSH) was founded in 1956 by a group of three led by Dr. Meng-Chao Wu, a member of Chinese Academy of Sciences. It is now the most prestigious university hospital and research institute specializing in hepatic and biliary diseases. The EHSH has 660 beds, 56 senior physicians and 16 PhD instructors serving over 70,000 out-patients and 12,000 in-patients annually. The hospital is a IIIA specialty hospital accredited by the Chinese Ministry of Health.

Over the years, they have performed nearly 17,000 hepatectomy cases, which have built the biggest case bank of liver cancer in the world. The success rate of hepatectomy is 98.5%, the overall 5-year survival rate is 48.6%, and the 5-year survival rate with early detection is 79.8%. The success and five-year survival rates of hepatectomy are among the best in the world. In 1990, they started research on immunochemotherapy to treat liver cancer and have successfully developed new immune vaccine that can recognize and kill cancer cells. In 1997, percutaneous ethanol injection (PEI) and transcatheter hepatic artery chemo-embolization (TACE) was introduced to treat liver cancer in this hospital. They use ethanol injection pre-operatively to prevent recurrence after surgical excision on patients with hepatocellular carcinoma. The 3-year recurrent rate of this therapy on tumour size < 5cm is 27%, which is significant. Up to now, they have done more than 6600 cases of TACE. Now, they are doing clinical research on using the gamma knife radio-surgery to treat liver cancer.

In the last 5 years, the hospital has treated 620 cases of complex hepatic injury involving intrahepatic bile duct, intrahepatic bile duct stricture, and 251 cases of intrahepatic cholangiocarcinoma. The largest liver hemangioma (18kg) ever recorded in the world till today was successfully removed in this hospital in 1975.

Hepatoblastoma are more common in patients aged under 3 years old. In 1980s, 12 cases of huge hepatoblastoma (800-1300 g) in babies aged from 4-12 month had been removed, with only one mortality that happened two years later after the surgery. All other kids are still alive and one of them is 15 years old now.

Since 1978, the hospital has become a teaching and researching center in hepatobiliary surgery for PhDs, residents and fellows from all around the world, and the host site of many national and international conferences on tumours. The hospital has graduated 78 PhDs, and many fellows from overseas. In addition to clinical departments, the hospital also composes Tumour Immunology and Gene Research Institute, Biological Signal Transmission Research Center, Molecular Tumor Research Lab, Virus-Gene Therapeutic Lab. There are billions of dollars for their research fund received from the Chinese government and overseas. All the scientific researches will benefit their patients clinically in many ways. They have also won diverse prizes and awards.

 
 
  Powered by ClaimTheWeb Cart - Shopping Cart Software